|
|||||
|
|

Cannabis company Tilray Brands (NASDAQ:TLRY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.7% year on year to $209.5 million. Its non-GAAP loss of $0 per share increased from -$0.04 in the same quarter last year.
Is now the time to buy TLRY? Find out in our full research report (it’s free for active Edge members).
Tilray’s third quarter results were met with a strong positive response from the market, reflecting the company's progress in expanding its diversified business model and achieving a notable improvement in operating margin. Management attributed the quarter’s performance to double-digit growth in Canadian adult-use and international cannabis segments, as well as operational improvements across its beverage and wellness divisions. CEO Irwin Simon highlighted that, outside of a flat beverage segment affected by SKU rationalization, all core business lines contributed to revenue growth, with focused efforts on product innovation and efficiency driving the company’s improved profitability.
Looking ahead, Tilray’s management emphasized a strategy centered on capturing emerging opportunities in both the global cannabis market and adjacent categories such as hemp-derived beverages and wellness products. CEO Irwin Simon pointed to ongoing regulatory developments, particularly in the U.S. and Europe, as key potential accelerators for future growth. The company aims to leverage its large-scale production capabilities, expanded distribution reach, and new product launches, with Simon stating, “We are committed to unlocking new possibilities through continuous innovation, portfolio expansion, and targeted investments, including the opportunities when strategic acquisitions happen.”
Management credited third quarter momentum to international cannabis expansion, operational streamlining in beverages, and targeted innovation in wellness and hemp-based products.
Tilray’s guidance centers on expanded international cannabis access, new product launches, and the evolving regulatory landscape as key drivers of future results.
In future quarters, the StockStory team will be watching (1) the pace of regulatory changes in key markets like Germany and the U.S., (2) the impact of new product introductions—especially in hemp-based beverages and wellness—on overall revenue mix, and (3) ongoing gains in operational efficiency and margin recovery in the beverage segment. Progress on international distribution expansion will also be a critical marker.
Tilray currently trades at $1.99, up from $1.73 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free for active Edge members).
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| Oct-30 | |
| Oct-27 | |
| Oct-23 | |
| Oct-22 | |
| Oct-22 | |
| Oct-22 | |
| Oct-20 | |
| Oct-19 | |
| Oct-17 | |
| Oct-16 | |
| Oct-16 | |
| Oct-15 | |
| Oct-15 | |
| Oct-15 | |
| Oct-13 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite